iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases.
The last earnings update was 141 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether iCo Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as iCo Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
iCo Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
iCo Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
iCo Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
Take a look at our analysis of 0IT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through iCo Therapeutics's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iCo Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare iCo Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare iCo Therapeutics's earnings growth to the Germany market average as no estimate data is available.
Unable to compare iCo Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if iCo Therapeutics is high growth as no earnings estimate data is available.
Unable to determine if iCo Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
iCo Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
iCo Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
iCo Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
iCo Therapeutics has no long term commitments.
This treemap shows a more detailed breakdown of
iCo Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
iCo Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Andrew J. Rae, BSc, MBA, Co-founded ICo Therapeutics Inc. in 2005 and serves as its Chief Executive Officer and President since February 2005. Mr. Rae serves as a Consultant to Ventures West Management. He has a decade of experience in the biotechnology field. He served as the Chief Financial Officer of Ability Biomedical Corp. of Irvine, California and Vancouver, British Columbia and as its Chief Executive Officer since February 2005. He served as Vice-President of Finance and Corporate Affairs at Active Pass Pharmaceuticals Inc. of Vancouver, British Columbia. He served as a Biotechnology Equities Analyst for Goepel Shields and Partners (now Raymond James Ltd., Research Division), covering Canadian biotechnology stocks including Angiotech Pharmaceuticals, Inc., QLT Inc. and ID Biomedical Corporation. He raised approximately $20,000,000 in venture finance, engaged in a successful cross border M&A transaction and played a significant role in shaping multiple business development deals. He has been Director of Ico Therapeutics Inc. since February 15, 2005. He served as a Director of Carrus Capital Corporation (formerly BioWest Therapeutics Inc) from February 1, 2010 to November 7, 2012. He served as a Director of Liponex Inc., since 2006 until August 15, 2007. Mr. Rae serves on Dean's External Advisory Board for the Faculty of Business Administration at Simon Fraser University and the Board of Directors of Covenant House Vancouver. He served as a Director of Migenix Inc. (now Metro Vancouver Properties Corp.) since August 11, 2008. He holds a B.Sc. Degree from University of Western Ontario and an MBA degree from Simon Fraser University.
Andrew's compensation has been consistent with company performance over the past year.
Andrew's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the iCo Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
CFO, Corporate Secretary & Director
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the iCo Therapeutics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.